It was fantastic to meet with Dr Philipp Schommers (University Hospital Cologne, University of Cologne, Cologne, Germany) to discuss the clinical development of broadly neutralizing antibodies in HIV and their potential as a curative strategy.
The presentation entitled: ‘The antibody component: bnAbs in HIV cure’ was presented at the 18th European AIDS Conference (EACS 2021), 27-30 October, 2021
Questions:
- Why do we need research about broadly neutralizing antibodies in HIV? (0:07)
- Could you tell us a little about bNAbs and their mechanism of action? (1:33)
- What is the status in the clinical development of bNAbs? (3:08)
- What is the potential of anti-HIV bNAbs as a curative strategy and what will be the future directions of research? (4:51)
Disclosures: Philipp Schommers has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of EACS (Hybrid) Conference 2021
